

IDEXX Laboratories (Westbrook, ME) has announced the election of Jonathan W. Ayers as chairman and CEO, succeeding company founder David Shaw. Mr. Ayers was most recently president of Carrier Corp., a division of United Technologies.

Progenics Pharmaceuticals (Tarrytown, NY) has announced the promotions of Thomas A. Boyd to the position of vice president, preclinical development and project management, and Philip K. Yachmetz to vice president and general counsel. Dr. Boyd joined Progenics in January 2000 as senior director, project management, and Mr. Yachmetz joined Progenics in September 2000 as the company's general counsel.

NitroMed (Bedford, MA) has appointed James J. Cappola senior vice president of clinical and regulatory affairs. Dr. Cappola joins NitroMed from the Covalent Group, where he was chief medical officer.

Richard U. De Schutter and Paul A. Brooke have been named to the board of directors of Incyte Genomics (Palo Alto, CA). Mr. De Schutter was previously chairman and CEO of DuPont Pharmaceuticals. Mr. Brooke is currently the general partner of PMSV Holdings, an advisory director at Morgan Stanley, and a venture partner at MPM Capital.

Livio D. DeSimone, retired CEO and chairman of 3M, and John Lawson, retired president of business aircraft sales for Bombardier Aerospace, have been named to the board of directors of Nexia Biotechnologies (Montreal, QC, Canada). Additionally, Nexia has appointed Mark Kaufmann to the newly created position of vice president, corporate development and biopharmaceuticals. Most recently, Mr. Kaufmann was CFO and vice president, corporate development at Conceptis Technologies.



Axel Ullrich

Startup company U3 Pharma (Martinsried, Germany) has announced the formation of its supervisory board with the appointments of Karsten Henco, Jean Deleage, and Axel Ullrich. Dr. Henco was formerly managing director and CEO of Evotec OAI, and was a co-founder and managing partner of Qiagen. Dr. Deleage is a founder of Alta Partners, and is or has served on the boards of directors of ACLARA, Rigel, Kosan BioSciences, Chiron, Genset, AGY Therapeutics, BioMedicines, and Crucell, among others. Prof. Ullrich, U3's founder, is currently a director of the Max Planck

Institute for Biochemistry in Munich as well as founder of the biotech companies SUGEN and Axxima.

Morphotek (Philadelphia, PA) has announced the appointment of David R. King to its board of directors. Mr. King is president of Delsys and a member of the board of 3-Dimensional Pharmaceuticals.

Anadys Pharmaceuticals (San Diego, CA) has announced the following appointments: David W. Kramer has been named as CFO, Elizabeth E. Reed as director of legal affairs, Brad Kerr as senior director of clinical affairs, and Wei Liaw as associate director of pharmaceutical development. Mr. Kramer joins Anadys from Gen-Probe, where he served as vice president, finance and CFO; Ms. Reed was a patent attorney with Cooley Godward; Dr. Kerr was most recently senior director in clinical research for Pfizer Global R&D; and Dr. Liaw was formerly vice president of pharmaceutical development at Medinco.

Walt Mahoney has been named to the newly created position of senior vice president, research and development at Epoch Biosciences (Bothell, WA). Dr. Mahoney was most recently chief scientific officer at Quantum Dot Corp., and from 1998 to early 2001 was responsible for Roche's US chief technology office.

Daniel R. Marshak has been appointed to the position of vice president and chief technology officer, biotechnology at Cambrex (East Rutherford, NJ) and chairman of the company's scientific advisory board. Dr. Marshak joined Cambrex in 2000 as vice president of R&D, biosciences. Additionally, Ron Carroll has been named vice president and chief technology officer, pharmaceutical technologies. Dr. Carroll joined Cambrex in September 1997 as vice president, technology.

Medarex (Princeton, NJ) has announced that Wen Ryan has joined the company as vice president of biopharmaceutical development. Dr. Ryan previously managed process development and manufacturing organizations at Amgen and Schering-Plough.

Memory Pharmaceuticals (Montvale, NJ) has named Gardiner F.H. Smith, most recently executive director, business development at Human Genome Sciences, to the position of vice president, business development.

Keith P. Wilson has been named vice president of technology at Syrrx (San Diego, CA). He joins Syrrx from Vertex Pharmaceuticals, where he was co-leader of the company's kinase development project.